AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04615026 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: duplex sonography
Description: all patients with consent receive a duplex ultrasound, blood test, cognitive test and test of smelling
Study NCT01349400 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Watchful waiting
Description: Watchful waiting means the observation of the hernia. The patient is informed about signs of deterioration or incarceration. The hernia is controlled clinically on defined follow-up visits.
Study NCT01349400 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hernia repair
Description: Open or laparoscopic hernia repair with mesh (non-absorbable or partly-absorbable alloplastic material) or with direct suture repair. For hernias measuring ≥ 3 cm mesh repair is recommended. A wide overlap of the mesh over the fascia margin on each side has to be provided.~These are all standard techniques in incisional hernia repair.
Study NCT03613519 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SHUTi
Description: A woman assigned to SHUTi receives access to an online program that includes 6 interactive sessions that are designed to be reviewed over a period of about 8 weeks. The online sessions include videos and written material that give information about factors that affect sleep, changes that might help sleep patterns, and how to make those changes. Each session takes about 45 to 60 minutes to complete. During and between sessions, the participant fills out sleep diaries to gather information about daily sleep patterns. At 3 different times, the woman is asked to fill out questionnaires about her sleep and health as well as sleep diaries. Time 1 is just before starting the first session of the SHUTi program. Time 2 is about 9 weeks later and Time 3 is about six months after that. The questionnaires will be used to assess the effect of the online program on the participant's sleep and health.
Study NCT03613519 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: modified SHUTi (i.e., SHUTi-BWHS)
Description: A woman assigned to modified SHUTi (i.e., to SHUTi-BWHS) receives access to an online program that includes 6 interactive sessions that are designed to be reviewed over a period of about 8 weeks. The online sessions include videos and written material that give information about factors that affect sleep, changes that might help sleep patterns, and how to make those changes. Each session takes about 45 to 60 minutes to complete. During and between sessions, the participant fills out sleep diaries to gather information about daily sleep patterns. At 3 different times, the woman is asked to fill out questionnaires about her sleep and health as well as sleep diaries. Time 1 is just before starting the first session of the modified SHUTi program. Time 2 is about 9 weeks later and Time 3 is about six months after that. The questionnaires will be used to assess the effect of the online program on the participant's sleep and health.
Study NCT03613519 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Patient education
Description: A woman assigned to patient education receives access to a website that provides detailed information on habits and environments that may help or hinder sleep. The site can be visited as often as desired. At 3 different times, the woman is asked to fill out questionnaires about her sleep and health, as well as sleep diaries to gather information about her daily sleep pattern. Time 1 is just before first logging into the sleep information website. Time 2 is about 9 weeks later and Time 3 is six months after that. The questionnaires will be used to assess the effect of the sleep information program on the participant's sleep and health.
Study NCT01047553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol (OT)
Description: 9 μg/dose, Inhaled, twice daily for 52 weeks
Study NCT02824796 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Schema Parent Behavioral Training
Description: A novel protocol for parent whose children suffer from ADHD and comorbidities. The protocol combines elements from Schema Focus Therapy (SFT) and Parent Behavioral Training (PBT)
Study NCT02824796 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent Behavioral Training
Description: A state of the art Parent Behavioral Treatment (PBT) for Children who suffer from ADHD symptoms
Study NCT00734877 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: M-VTD-PACE
Description: 2 cycles of induction therapy with M-VTD-PACE and PBSC collection after the 1st cycle. MEL-based tandem transplant will be administered 6 weeks to 3 months apart, applying single dose MEL 200 mg/m2 with adjustments for age and renal function. Consolidation will consist of 2 cycles of dose-reduced VTD-PACE. Maintenance treatment will employ VRD for 3 years.
Study NCT00734877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT3-LITE Regimen (L-TT3)
Description: The TT3-LITE Regimen (L-TT3) will employ only 1 cycle of induction therapy with MVTD-PACE and, as in S-TT3, PBSC collection following recovery from this one and only induction treatment. MEL-based tandem transplant will be administered 6 weeks to 3 months apart, applying fractionated MEL200mg/m2 in 4 successive daily fractions of 50mg/m2 (MEL50 x 4) with addition of VTD with adjustments for age and renal function. Consolidation will consist of only 1 cycle of dose-reduced VTD-PACE. Maintenance treatment will employ VRD for 3 years.
Study NCT00356304 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Description: Participants assigned to motivational interviewing will attend two 1-hour sessions of motivational interviewing over 2 consecutive weeks, followed by a third session 8 weeks later. Motivational interviewing is a type of counselling. Each session is of approximately 1 hour duration.
Study NCT00356304 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Participants will continue with their normal treatment regimen as usual.
Study NCT03437616 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tulppa rehabilitation
Description: The intervention includes health education on e.g. healthy diet, weight management, physical activity and psychosocial coping as well as peer discussions and physical exercises.
Study NCT01267214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Hyaluronate (Hyalgan)
Description: 1% Sodium Hyaluronate in prefilled syringe
Study NCT01267214 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Osteotomy alone
Description: no injection
Study NCT02633202 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IMRT
Description: Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.30 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor
Study NCT02633202 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.30 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor
Study NCT02633202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles during IMRT
Study NCT00534482 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Office
Description: Clinicians and office staff personally engage in AIM-HI fitness program, and promote program to patients
Study NCT00534482 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Office
Description: Conventional office: Clinicians and office staff are not personally engaged in the AIM-HI fitness program, but promote program to patients.
Study NCT00534482 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AIM-HI program with enhanced feedback
Description: Patient receives feedback on two novel indicators of their individual cardiovascular risk that: 1)appear to relate to obesity and lack of physical activity, and 2) may show relatively rapid change with improvements in these areas. These are the Homeostatic Assay - Insulin Resistance or HOMA-IR and Nuclear Molecular Resonance (NMR) lipoprotein profiles (NMRLP). These patients and their physicians also will receive periodic feedback on other outcome measures, including BMI, blood pressure, a 3-minute step test, eating assessment, physical activity assessment, and emotional well-being assessment.
Study NCT00534482 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: AIM-HI program and regular feedback
Description: Patients will not receive feedback on two specific cardiovascular risk indicators (ie, Homeostatic Assay - Insulin Resistance, Nuclear Molecular Resonance lipoprotein profiles). However, patients will receive feedback on Body Mass Index, blood pressure, a 3-minute step test, eating assessment, physical activity assessment, and emotional well-being assessment.
Study NCT02640456 — intervention group
Intervention type: BIOLOGICAL
Intervention: Bacteriology
Description: Tonsillar surface swabs, tonsillar tissues, and pus aspirates.
Study NCT02640456 — intervention group
Intervention type: PROCEDURE
Intervention: Type of surgery
Description: Surgical approach and complications.
Study NCT02640456 — intervention group
Intervention type: BIOLOGICAL
Intervention: Biochemistry
Description: Amylase concentration i pus aspirates.
Study NCT02640456 — intervention group
Intervention type: BIOLOGICAL
Intervention: Serology
Description: Levels of antibodies against selected bacteria (F. necrophorum, F. nucleatum, and Group A streptococci) in acute and convalescent sera.
Study NCT02453711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Once-daily subcutaneous (s.c., under the skin) administration with dose escalation.
Study NCT02453711 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liraglutide
Description: Once-daily subcutaneous (s.c., under the skin) administration with dose escalation.
Study NCT02453711 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Once-daily subcutaneous (s.c., under the skin) administration.
Study NCT02544516 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive tasks + PANSS+ IQ
Description: Patients will have cognitive tasks: reaction time (Alert TEA, Zimmermann and Fimm, 2005), Edinburgh laterality questionnaire (Oldfield, 1971), IQ test (IQ: PM38, Raven, 1960), and the PANSS (Positive and Negative Syndrome Scale, Kay et al., 1987
Study NCT02544516 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cognitive tasks
Description: Patients will have cognitive tasks: reaction time (Alert TEA, Zimmermann and Fimm, 2005), Edinburgh laterality questionnaire (Oldfield, 1971),
Study NCT02731105 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acnatac® Gel left face
Description: topical application
Study NCT02731105 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epiduo® Gel right face
Description: topical application
Study NCT02731105 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acnatac® Gel right face
Description: topical application
Study NCT02731105 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epiduo® Gel left face
Description: topical application
Study NCT04539769 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional BI
Description: After standard laparoscopic distal gastrectomy with radical lymphadenectomy, the gastrointestinal continuity will be restored with conventional Billroth I gastroduodenostomy.
Study NCT04539769 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: long-limb BII
Description: After standard laparoscopic distal gastrectomy with radical lymphadenectomy, the gastrointestinal continuity will be restored with Billroth II gastrojejunostomy using 100 cm-long biliopancreatic limb.
Study NCT04539769 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: long-limb RY group
Description: After standard laparoscopic distal gastrectomy with radical lymphadenectomy, the gastrointestinal continuity will be restored with Roux-en-Y reconstruction using 100 cm-long Roux limb and standard biliopancreatic limb.
Study NCT00218842 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized exercise
Description: individualized exercise, physical activity and training in daily life situations given by trained physical therapists and occupational therapists
Study NCT04350957 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Low-dose Imaging
Description: We are comparing MRI image quality for diagnostic purposes. We hope to learn whether using a lesser dose (25%) of the FDA approved contrast agent, Gadavist®, is just as effective as a standard or full dose (100%) of the same contrast in a breast MRI.~This research is being done because breast MRI's have repeatedly been shown to represent the most reliable imaging method for breast cancer screening and diagnosis, regardless of personal risk for breast cancer and radiographic breast density. However, there are growing concerns about getting frequent breast MRI examinations due to the deposition of gadolinium, a metal ion that is found in all breast MRI contrast agents. The FDA states that this deposition and retention is not known to have any long term side effects on patient. However, the researchers at the University of Chicago Medicine would like to further investigate this using a lesser dose of contrast agent than the recommended dose for breast MRI examinations.
Study NCT00932178 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calmer Life
Description: Calmer Life is a modified version of an existing Cognitive Behavioral Treatment manual. Participants have the option of including religion and spirituality into coping skills taught as a way of treating anxiety with or without depression in older adults.
Study NCT02794532 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula
Description: Oxygenation will be done via a high-flow nasal cannula
Study NCT06418256 — intervention group
Intervention type: OTHER
Intervention: Spleen, blood and plasma collection
Description: Adult patients for whom a splenic intervention (spleno-pancreectomy, or a total or partial splenectomy) is planned as part of their care. One or more tubes of venous blood collected for the care will be recovered following the pre- or intra-operative assessment. Immediately following surgery, after careful examination by the pathologist in charge, the whole spleen or spleen fragments will be collected for further analysis. Whenever possible a catheter will be introduced in the splenic artery, the spleen will be flushed/rinsed with 0.1 - 2 L of cold perfusion medium then transferred to the laboratory for ex-vivo perfusion. Before and at the end of the ex-vivo perfusion, splenic blood and spleen fragments will be collected and processed for further analyses.
Study NCT02652858 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-invasive blood pressure oscillometer (NIBP) implementation
Description: Implementation of two additional NIBP on humeral and femoral sites.
Study NCT02736578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab-IRDye800
Description: Administered intravenously (IV) at 50 or 100 mg
Study NCT02736578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Administered as a 100 mg IV loading dose
Study NCT03751930 — intervention group
Intervention type: OTHER
Intervention: Samples
Description: Urinary and faecal samples
Study NCT00126724 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: tgAAC94 gene therapy vector
Description: Single Dose 1x10\^11 DRP/mL
Study NCT00126724 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: tgAAC94 gene therapy vector
Description: Second dose of 1x10\^11 DRP/mL tgAAC94 administered once target joint reaches predetermined criteria for re-injection (on or after Week 12) at the same concentration as initial dose.
Study NCT00126724 — intervention group
Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: tgAAC94 placebo
Description: placebo
Study NCT00126724 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: tgAAC94 gene therapy vector
Description: Single Dose 1x10\^12 DRP/mL tgAAC94
Study NCT00126724 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: tgAAC94 gene therapy vector
Description: Second dose of 1x10\^12 DRP/mL tgAAC94 administered once target joint reaches predetermined criteria for re-injection (on or after Week 12) at the same concentration as initial dose.
Study NCT00126724 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: tgAAC94 gene therapy vector
Description: Single Dose 1x10\^13 DRP/mL tgAAC94
Study NCT00126724 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: tgAAC94 gene therapy vector
Description: Second dose of 1x10\^13 DRP/mL tgAAC94 administered once target joint reaches predetermined criteria for re-injection (on or after Week 12) at the same concentration as initial dose.
Study NCT05429385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX70
Description: Single-dose, intravenous infusion
Study NCT05429385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single-dose, intravenous infusion
Study NCT02616796 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social gaze training
Description: Appropriate social gaze behavior will be shaped using the principles of Applied Behavior Analysis.
Study NCT01906606 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parenting Program
Description: A manualized, community-based 12 session group parenting program, facilitated by a locally recruited volunteer
Study NCT01253577 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sinus Stent with drug coating
Description: Sinus stent coated with 370 ug of the corticosteroid mometasone furoate
Study NCT01253577 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Non Coated Sinus Stent
Description: Sinus stent (visually identical) without drug coating
Study NCT04656327 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention in this study. It is a cross-section study evaluating the oral health and nutritional statuses of community-dwelling elders dependent for care for their activities of daily living.
Study NCT01311141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doripenem
Description: doripenem once i.v.500mg
Study NCT03182569 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FLEXIBLE CATHETER
Study NCT03182569 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hourly rigid needle puncture
Study NCT00851227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conivaptan hydrochloride
Description: intravenous
Study NCT04485351 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT02379637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Study NCT02379637 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03959397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: nab-paclitaxel monotherapy or combination therapeutic regimen
Study NCT03064061 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Virtual reality
Description: a device with virtual reality is given to the patients with a film of 18 minutes
Study NCT03064061 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Virtual reality
Description: a device with virtual reality is given to the patients with a film of 18 minutes
Study NCT01091220 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Description: 400 mg certolizumab pegol in 2 x 200 mg/mL, prefilled syringes, administered once, subcutaneously
Study NCT01091220 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 x prefilled syringes containing 0.9% saline, administered once, subcutaneously
Study NCT02612519 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alfapump
Description: Implantation of Alfapump
Study NCT02612519 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TIPS
Description: Implantation of TIPS
Study NCT04251026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tividenofusp alfa
Description: Intravenous repeating dose
Study NCT04610593 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Intervention
Description: A mindfulness-based intervention will be developed for chronic hemodialysis patients to be performed during hemotherapy sessions. This is an integrative mind-body program, which is based on the MBRP (Bowen et al., 2014) and BMT (T. Russell, 2015) protocols. The program will be conducted in eight weeks, with a weekly individual session of up to 60 minutes facilitated by an instructor, at the bedside during the HD session. The program aims to develop awareness of bodily sensations, emotions and thoughts, with an attitude of openness, curiosity, kindness and non-judgment. During the sessions will be worked four main techniques of mindfulness meditation: mindfulness in breathing, body scanning, conscious movements and practice of compassion. Participants are invited and encouraged to practice Mindfulness using audios made available during the other HD sessions they undergo during the week, in addition to daily home practice.
Study NCT02722018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0810 Phase II Tablet
Description: Participants will receive dose level A (in Parts 1 and 2) or dose level B (in Part 3) tablets.
Study NCT02722018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0810 Phase III Prototype Tablet
Description: Participants will receive dose level A (in Parts 1 and 2) or dose level B (in Part 3) tablets.